Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + panobinostat
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of sorafenib, a multikinase inhibitor that targets cell surface tyrosine kinase receptors and downstream intracellular kinases involved in tumor cell proliferation and angiogenesis[2]. It's approved for treating unressectable liver carcinoma (hepatocellular carcinoma), advanced renal carcinoma, and differentiated thyroid carcinoma[2][5]. 2. **Panobinostat (LBH589)** is a pan-HDAC (histone deacetylase) inhibitor that affects the acetylation of approximately 1,750 proteins in the body[4]. It works by inhibiting class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10), and class IV (HDAC 11) proteins[4].
- Brand names
- Nexavar + Farydak
- Other names
- panobinostat tosylatesorafenib tosylate
02
Targets
HDAC6 (Histone deacetylase 6)PDGFRB (Platelet-derived growth factor receptor beta)BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)HDAC1 (Histone Deacetylase 1)HDAC8 (Histone Deacetylase 8)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR2 (Vascular endothelial growth factor receptor 2)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sorafenib + panobinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + panobinostat.